BRD2 has been reported to modulate extracellular matrix gene expression and promote mesenchymal transition through the PTEN–NF-κB–BRD2 signaling axis, thereby enhancing GBM cell invasiveness [137]. The gene discussed is PTEN; the disease is glioblastoma.